SRDAN VERSTOVSEK to Drug Evaluation, Preclinical
This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Drug Evaluation, Preclinical.
Connection Strength
0.256
-
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. Future Oncol. 2015; 11(5):719-33.
Score: 0.108
-
Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program. 2009; 636-42.
Score: 0.071
-
Experimental therapy in myelofibrosis with myeloid metaplasia. Expert Opin Investig Drugs. 2006 Dec; 15(12):1555-63.
Score: 0.061
-
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia. 2007 Jul; 21(7):1395-404.
Score: 0.016